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Abstract Molecular evidence has linked the pathophys-
iology of lymphangioleiomyomatosis (LAM) to that of
metastatic breast cancer. Following on this observation, we
assessed the association between LAM and subsequent
breast cancer. An epidemiological study was carried out
using three LAM country cohorts, from Japan, Spain, and
the United Kingdom. The number of incident breast cancer
cases observed in these cohorts was compared with the
number expected on the basis of the country-specific
incidence rates for the period 2000–2014. Immunohisto-
chemical studies and exome sequence analysis were per-
formed in two and one tumors, respectively. All cohorts
revealed breast cancer standardized incidence ratios
(SIRs) C 2.25. The combined analysis of all cases or
restricted to pre-menopausal age groups revealed signifi-
cantly higher incidence of breast cancer: SIR = 2.81, 95 %
confidence interval (CI) = 1.32–5.57, P = 0.009; and
SIR = 4.88, 95 % CI = 2.29–9.99, P = 0.0007,
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respectively. Immunohistochemical analyses showed pos-
itivity for known markers of lung metastatic potential. This
study suggests the existence of increased breast cancer risk
among LAM patients. Prospective studies may be war-
ranted to corroborate this result, which may be particularly
relevant for pre-menopausal women with LAM.
Keywords Breast cancer  Incidence 
Lymphangioleiomyomatosis  mTOR  TSC1  TSC2
Introduction
LAM is a rare neoplastic disease that appears predomi-
nantly in women of childbearing age and is characterized
by cystic lung destruction [1, 2]. LAM lesions are hetero-
geneous at the cellular phenotypic level but are typically
characterized by the proliferation of estrogen receptor a
(ERa)- and progesterone receptor (PR)-positive smooth
muscle-like cells with lung metastatic potential whose
tissue origin remains unclear [3]. LAM cells commonly
carry loss-of-function mutations in the tumor suppressor
genes TSC1 or TSC2, and consequently, exhibit abnormal
activation of the mechanistic target of rapamycin complex
1 (mTORC1) [4]. Thus, LAM can occur as an isolated
disease (termed sporadic LAM) or in association with
another rare disorder, tuberous sclerosis complex.
mTORC1 regulates a cancer metastasis transcriptional
program [5]. In breast cancer, low expression of TSC1 or
TSC2 is associated with poor clinical outcome [6], and
depletion of TSC2 expression promotes lung metastasis [7].
These observations led us to the test whether the mediators
of breast cancer metastasis to lung could also play a role in
LAM. Thus, we identified molecular positivity in LAM
lesions for known metastasis mediators [8]. Low TSC1/2
expression in primary breast tumors was found to be
associated with enhanced mTORC1 signaling and lung (but
not bone) metastasis. Collectively, the clinical, pathologi-
cal, and molecular similarities between LAM and breast
cancer prompted us to hypothesize a higher incidence of
breast cancer in LAM patients. To assess this hypothesis,
we compiled the largest epidemiological LAM study to
date.
Methods
LAM cohorts
The cohorts comprised LAM patients from three countries
(Japan, Spain, and the United Kingdom). Patients were
diagnosed by computed tomography scan. In most cases
([80 % of patients in any cohort), diagnosis was comple-
mented by the presence of at least one of the following
findings: lymphatic complication, lung biopsy, renal
angiomyolipoma, and/or TSC [2, 9, 10]. Collectively, the
number of diagnoses per population was consistent with the
reported prevalence of the disease in developed countries
(1–9 in 106 individuals) [10]: 108, 175, and 175 in Japan,
Spain, and the United Kingdom, respectively. The ethics
committee of the Hospital de Henares approved the inter-
national epidemiological study (approval number PI-753).
The data from the Japan and United Kingdom cohorts
(irreversibly encoded) were provided for combined analy-
sis at the Spanish study center. Informed consent was not
required for the epidemiological study (PI-753), as it was
based on irreversibly encoded retrospective records; how-
ever, approved informed consent was obtained from those
patients that provided tumor samples for genetic and
immunohistochemical analyses. These studies were
approved by the ethics committees of the Bellvitge Institute
for Biomedical Research (IDIBELL; PR082/13), the
Instituto de Investigacio´n Sanitaria La Princesa (SEPAR-
2012), and the Hospital de Henares (PI-753). In addition,
all LAM patients in the Japanese cohort provided informed
consent for the comprehensive analysis of their clinical
data (National Hospital Organization Kinki-Chuo Chest
Medical Center, approval number 365).
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Follow-up and breast cancer ascertainment
In all clinical settings, LAM patients underwent regular
follow-up evaluations with a periodicity of 3–12 months,
depending on the country and each patient’s condition. In
addition, follow-up was updated via telephone, and patient
conditions, including death, were recorded in each data-
base. Given that LAM has only been monitored for a short
time [9], and since breast cancer screening programs were
not fully implemented in some countries until relatively
recently, only patients diagnosed from 2000 were consid-
ered in this study, which corresponded to[80 % of the
cases in each cohort (Supplementary Table 1). In all cases,
follow-up started with LAM diagnosis and finished with
the first occurrence of one of the following events: death,
breast cancer diagnosis, date of last contact, or end of the
study (December 31st, 2014). Breast cancer diagnosis
required pathological confirmation. Since national breast
cancer rates do not include in situ tumors, only invasive
cases were considered.
Statistical analysis
The incidence of breast cancer in the LAM cohorts was
compared with the incidence observed in the general
population, using standardized incidence ratios (SIRs) [11].
This ratio corresponds to the observed versus expected
number of cases, where the expected number is obtained
considering age (5-year groups) and period- (2000–2004,
2005–2009, and 2010–2014) specific incidence breast
cancer rates in each country. The same analysis was
repeated considering pre-menopausal age groups (women
younger than 50). Person-years in each stratum were cal-
culated using the survival package (version 2.38, R soft-
ware), and SIR confidence intervals were computed under
the Poisson assumption and using the exact method [12].
Antibodies
The antibodies used in this study were anti-ERa (#IR151,
Dako), anti-FSCN1 (#SC-56531, Santa Cruz Biotechnol-
ogy), anti-HMB-45 (#SC-59305, Santa Cruz Biotechnol-
ogy), anti ID1 (#SC-488, Santa Cruz Biotechnology), anti-
PR (#IR168, Dako), anti-phospho-Ser235-236 S6 riboso-
mal protein (anti-pS6; clone 91B2, Cell Signaling Tech-
nology), anti-SMA (#A2547, Sigma-Aldrich), and anti-
SOX9 (#AB5535, Millipore).
Immunohistochemistry
Immunohistochemical assays were performed using stan-
dard protocols with the EnVision (Dako) method. Each
tissue and biomarker was evaluated in at least two
independent assays and no substantial differences were
observed. Equivalent sections were processed to include
incubation with immunoglobulin controls (Sigma-Aldrich),
which did not reveal staining in any case. The immuno-
histochemistry results were evaluated independently by at
least two expert pathologists.
Exome sequencing
Breast cancer ([50 % tumor cells) DNA was extracted
from a surgical sample following standard protocols and
the exome sequence analyzed by GATC Biotech. The
coverage was of[109 for at least 90 % of the genome and
some TSC1/2 exonic regions were targeted by Sanger
sequencing to obtain full annotation. Variant mapping,
alignment, calling, annotation, and filtration were per-
formed using the genome reference hg19 (GRCh37) and
the GATK modules [13].
Results
Analysis of standardized incidence ratios
The three LAM cohorts revealed breast cancer
SIRs C 2.25 (Table 1, which also includes the observed
and expected numbers per cohort and for the combined
analysis). In fact, the United Kingdom cohort revealed a
significant SIR of 3.16; 95 % confidence interval
(CI) = 1.08–8.15, P = 0.039. Thus, the global estimation
of an excess of breast cancer cases was found to be sig-
nificant: SIR = 2.81, 95 % CI = 1.32–5.57, P = 0.009
(Table 1).
Since LAM is generally diagnosed in women of fertile
age and an increased risk of breast cancer may be associ-
ated with earlier age of onset [14], an analysis restricted to
pre-menopausal age groups (women younger than 50) was
performed. A significantly higher incidence of breast can-
cer in the cohorts of Spain and the United Kingdom was
observed, with SIRs = 4.98 and 7.09; P values = 0.023
and 0.003, respectively. Moreover, the global analysis was
also found to be significant: SIR = 4.88, 95 %
CI = 2.29–9.99, P = 0.0007 (Table 1).
Immunohistochemical features of breast tumors
from LAM patients
Approximately, two-thirds of the breast tumors that
develop in pre-menopausal women in the general popula-
tion are hormone receptor-positive [15]. In our study, all
tumors with available pathological information (n = 8)
were recorded as ERa- and PR-positive. While none pre-
sented family history of the disease, relatively uncommon
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clinical and histopathological features were noted. Three
Spanish cases were diagnosed with multifocal breast can-
cer, one of them was diagnosed at age 37 with rapid pro-
gression following 8 months of rapamycin treatment for
LAM [10]. Whole exome sequencing did not identify
TSC1/2 mutations in a fresh tumor sample for this case;
importantly, exonic TSC1/2 mutations are common but not
seen in all sporadic LAM patients [16]. The tumor exome
analysis did uncover a known oncogenic mutation in
PIK3CA (c.3140A[G, H1047R), which was confirmed
by Sanger sequencing (Supplementary Fig. 1); however,
mutations in this gene are found relatively frequent in ERa-
positive breast cancer [17].
Immunohistochemical analyses of the above depicted
tumor and of an additional case showed positivity for both
ERa and PR in cells with apparently different phenotypes
(Fig. 1). Both cases were also positive for a canonical
marker of mTORC1 activity and for the lung metastatic
mediators revealed in our original study (FSCN1, ID1, and
SOX9; Fig. 2). Heterogeneity was also apparent and pos-
itive cells were linked to either an epithelial or a spindle
phenotype (Fig. 2). Together, the observations of multifo-
cal ERa-positive tumors in pre-menopausal LAM patients
without family history of the disease would further suggest
a link to a specific breast cancer subtype.
Discussion
In previous analyses, we tested the hypothesis that the
metastatic properties of LAM cells could be further
depicted using knowledge of breast cancer tropism to lung,
and thus identified the expression of metastatic mediators
and cancer cell stemness molecular determinants in LAM
lesions [8]. Following on from this evidence, and given that
the tissue of origin of LAM cells remains a subject of
debate [3, 18, 19], we aimed to assess breast cancer inci-
dence in LAM patients. The results of our study of three
cohorts in different countries suggest that LAM patients,
particularly those in the pre-menopausal age range, are at
higher risk of developing invasive breast cancer than
women from the general population. This might therefore
indicate a shared cell origin and/or shared genetic risk
factors between the two diseases. However, we cannot rule
out that the retrospective nature of the survey and/or the
regular clinical monitoring of LAM patients may have led
to an over-estimation of breast cancer incidence.
Apart from brain and kidney malignancies [20], there is
no previous evidence of other cancer susceptibilities in
patients with tuberous sclerosis complex; indeed, among
the LAM patients with breast cancer in our study, only one
(1/15; 6, 7 %) was diagnosed with this disease (i.e., carrier
of a germline TSC2 mutation), so the others were sporadic
LAM cases. Intriguingly, however, a recent study of 1,000
breast cancer patients incidentally identified a pathogenic
germline TSC2 mutation [21]; therefore, further germline
studies of TSC1/2 may be warranted to assess the potential
link with breast cancer risk. In our study, exome analysis of
a breast tumor sample did not reveal mutations in these
genes, but exonic mutations are not detected in all sporadic
LAM patients [16], which further suggests heterogeneity in
the biology of LAM.
Hypothetically, multiple tissue or organ origins can co-
exist if it is considered that enhanced mTORC1 activity
mediates metastatic behavior in different cancer types [5].
Nevertheless, the link between LAM and women at
childbearing age [2, 10] suggests tissue and/or cell type
specificity. Dependence on hormone signaling is a hall-
mark of several cell types in breast tissue [22]. In this
scenario, the repeated cycles of vast cell proliferation that
Table 1 Number of breast
cancer cases observed and
expected, and SIRs in the three
LAM cohorts
All cases
Country Person-years Observed
cases (n)
Expected
cases (n)
SIR 95 % CI P value
Japan 605.02 1 0.44 2.25 0.12–12.96 0.36
Spain 899.01 3 1.13 2.64 0.72–7.77 0.11
United Kingdom 809.22 4 1.26 3.16 1.08–8.15 0.039
Combined 2313.26 8 2.84 2.81 1.32–5.57 0.009
Pre-menopausal (\50 years old)
Country Person-years Breast cancer
cases/cohort (n)
Expected
cases (n)
SIR 95 % CI P value
Japan 453.32 0 0.27 – – –
Spain 620.00 3 0.60 4.98 1.36–14.63 0.023
United Kingdom 568.36 4 0.56 7.09 2.42–18.28 0.003
Combined 1641.68 7 1.43 4.88 2.29–9.99 0.0007
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occur in normal breast tissue at reproductive age provide
the time window for acquiring somatic genetic mutations
by chance. Thus, if a mutation is acquired in a specific
population of ERa/PR-positive cell progenitors [22] lead-
ing to an increase in mTORC1 activity, the corresponding
cells would possess metastatic behavior with lung tropism.
Fig. 1 Histopathological and immunohistochemical characterization
of breast tumors in two LAM patients. a Hematoxylin-eosin (HE) and
p63 (patient #1 only) staining results from the corresponding tumors
in LAM patients. Arrows mark magnified fields shown in the insets.
Three panels are shown for patient #2, which correspond to
(i) invasive, (ii) in situ, and (iii) desmoplastic histologies. The p63
marker was used as evidence of a metaplastic carcinoma. b Immunos-
taining results for ERa and PR in the corresponding breast tumors.
Red arrows mark magnified fields shown in the insets and black
arrows mark positive cells with a spindle-like phenotype
Breast Cancer Res Treat (2016) 156:195–201 199
123
Abnormal activation of mTORC1 would not produce
invasive tumors unless additional mutations are acquired,
which we speculate might have occurred in the identified
cases of LAM and breast cancer. Overall, prospective
studies may be warranted to corroborate our findings,
which may be particularly relevant for pre-menopausal
women with LAM.
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